Medical News / Coverage ASRS 2019: Chirag Jhaveri, MD: 96-Week Visual and Anatomical Outcomes of Brolucizumab

Heading into the 2019 American Society of Retina Specialists Annual Meeting, sessions and studies pertaining to brolucizumab were an item on the radar of many retina specialists in the constant search for treatments to improve the vision and quality of life for patients. 

 As such, the presentation by Chirag Jhaveri, MD, assistant professor of ophthalmology at the University of Texas Dell Medical School, on the 96-week expanded anatomical and visual outcomes of the HAWK and HARRIER trials was one of the most anticipated sessions of the conference. Source: MDmag By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization

read more

Findings of recent research demonstrate an intervention program, Balance after Baby, is promising for decreasing diabetes ... read more
A new analysis of data from the PIONEER program indicates reductions in HbA1c and body weight ... read more
Findings of a recent study suggest empagliflozin is associated with a decreased risk of hospitalization for ... read more
Testosterone treatment may prevent progression to or reverse type 2 diabetes in high-risk men who are ... read more